Last month the Pulmonary Hypertension Association (PHA) advocated for improved health insurance coverage for veterans and military personnel who have pulmonary arterial hypertension (PAH). PHA submitted comments June 28 to the Uniform Formulary Beneficiary Advisory Panel (BAP), which plays a role deciding which medications will be covered for individuals with military and veterans’ health insurance. Coverage for PAH therapies is currently under review.
The Uniform Formulary covers all PAH therapies at the on-formulary level, so a three-month, mail-order supply costs no more than $24. However, access to some therapies requires trying and failing on other therapies first, which can delay or disrupt effective therapy. PHA believes that individuals with PAH should have prompt access to the specific therapy prescribed by their physicians; PHA’s comments to the BAP reflect this message. Read PHA’s comments to the BAP.
